CHIASMA, INC
CHMA evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Lead Asset:
- mycapssa (Phase 3)
What it means
What to watch
Prepared research question
What matters most for CHMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
mycapssa (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate · 3 clinical trials for CHIASMA, INC.
Similar companies
Run CHIASMA, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHIASMA, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is CHIASMA, INC's lead drug candidate?
CHIASMA, INC's most advanced tracked candidate is mycapssa (Phase 3) for acromegaly.
Who is the CEO of CHIASMA, INC?
From January is the chief executive officer of CHIASMA, INC (CHMA).
What therapeutic areas does CHIASMA, INC focus on?
CHIASMA, INC develops therapies across Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.